Spiriva (Asthma) Market Growth, Analysis, Competitive Landscape, SWOT Analysis, Forecast 2023

ResearchBeam adds a report titled “Spiriva (Asthma) — Forecast and Market Analysis to 2023”. The report provides an in-depth study on the Spiriva (Asthma) Market trends, opportunities and factors influencing the market.

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) — Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Boehringer Ingelheim’s Spiriva (tiotropium bromide) is marketed for the treatment of COPD in all the markets covered by this report. This drug is a long-acting antimuscarinic/anticholinergic agent that causes bronchodilation by inhibiting the M3 muscarinic receptors located in the smooth muscles of the airway. It works by enlarging the airways to allow for easier breathing. GlobalData’s primary research revealed that physicians use Spiriva off-label for the treatment of moderate to severe persistent asthma.

Enquire About Report:
http://www.researchbeam.com/spiriva-asthma-forecast-and-analysis-to-2023-market/enquire-about-report

Scope

• Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Spiriva including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Spiriva for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Tables of Contents:

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17

For More Information Visit Our Blog :
http://rbeam.blogspot.com